Published in AIDS Weekly, December 2nd, 2002
"Aptamers, small oligonucleotides derived from an in vitro evolution process called SELEX, are promising therapeutic and diagnostic agents," explained Laurent Chaloin and colleagues at the Max Planck Institute for Molecular Biology in Dortmund, the German Cancer Research Center in Heidelberg, and the University of Luebeck's Institute for Molecular Medicine in Luebeck.
One such agent was able to disrupt HIV reverse transcriptase activity, preventing the efficient release of viral particles from infected cells, Chaloin and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2002-12-02)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.